Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: Breast Cancer Research

Université Laval

$100,000.00

TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer

EF 2022-23

Résumé
Triple negative breast cancers (TNBC) are responsible for 10 to 20% of all breast cancers. TNBC is a complex disease, mainly due to its heterogeneity, high rate of relapse, metastasis, and bad survival. In particular, metastatic TNBC patients will survive around 33 months after treatment failure. There is as yet no common approved therapeutic target regimen applicable to all TNBC patients. This lack of treatment has led to many investigations to identify genes specific to this devastating disease. Our group has identified a gene (TBC1D9) differentiating all TNBC patients from other breast cancer subgroups. Such gene could potentially be developed and serve as therapeutic option. Our group has shown that TBC1D9 is less expressed in TNBC as compared to non-TNBC patients. Further analysis showed that breast cancer patients with higher expression of TBC1D9 have a better survival rate. Therefore, we hypothesize that this gene is a true indicator of the aggressiveness of TNBC and understanding its role is key to potentially come up with new therapeutic options for TNBC, irrespective of their heterogeneity. Considering that TNBC currently lacks any specific treatment options, priority should be given to understand the tue potential of this gene as possible therapeutic target because success in treating malignant diseases has the potential to prevent lethality.
Programme
Project Grant - PA: Breast Cancer Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
472373
Name
Durocher Francine
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Biomarker; Breast Cancer; Tbc1 Domain Family Member 9; Tbc1d9; Therapeutic Target; Treatment Option; Triple Negative Breast Cancer
Abstract
Triple negative breast cancers (TNBC) are responsible for 10 to 20% of all breast cancers. TNBC is a complex disease, mainly due to its heterogeneity, high rate of relapse, metastasis, and bad survival. In particular, metastatic TNBC patients will survive around 33 months after treatment failure. There is as yet no common approved therapeutic target regimen applicable to all TNBC patients. This lack of treatment has led to many investigations to identify genes specific to this devastating disease. Our group has identified a gene (TBC1D9) differentiating all TNBC patients from other breast cancer subgroups. Such gene could potentially be developed and serve as therapeutic option. Our group has shown that TBC1D9 is less expressed in TNBC as compared to non-TNBC patients. Further analysis showed that breast cancer patients with higher expression of TBC1D9 have a better survival rate. Therefore, we hypothesize that this gene is a true indicator of the aggressiveness of TNBC and understanding its role is key to potentially come up with new therapeutic options for TNBC, irrespective of their heterogeneity. Considering that TNBC currently lacks any specific treatment options, priority should be given to understand the tue potential of this gene as possible therapeutic target because success in treating malignant diseases has the potential to prevent lethality.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Durocher, Francine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~